VKTX
Viking Therapeutics·NASDAQ
--
--(--)
--
--(--)
VKTX fundamentals
Viking Therapeutics (VKTX) released its earnings on Feb 11, 2026: revenue was 0 (YoY --), met estimates; EPS was -1.38 (YoY -331.25%), missed estimates.
Revenue / YoY
0
--
EPS / YoY
-1.38
-331.25%
Report date
Feb 11, 2026
VKTX Earnings Call Summary for Q4,2025
- Phase III Milestones Achieved: VANQUISH-1 fully enrolled (4,500+ pts), VANQUISH-2 nearing completion. Oral VK2735 Phase II achieved 12.2% weight loss, advancing to Phase III Q3.
- Innovative Dosing Options: Auto-injector transition underway; maintenance study evaluates monthly, weekly, and oral regimens.
- Manufacturing Scale: $700M+ cash position supports $3B+ revenue potential via CordenPharma agreement.
- Amylin Program Expansion: IND filing Q1, Phase I data expected 2026.
- Commercial Readiness: CCO Neil Aubuchon leads go-to-market strategy with digital health partnerships.
- Financial Discipline: 2025 R&D spend ($345M) balanced with $706M cash reserves.
- Strategic Differentiation: First GLP-1/GIP agonist with seamless oral/subcu transitions, extended half-life.
- Growth Catalysts: 2026 Phase III readouts, oral program expansion, amylin data.
- Risk Management: Diversified pipeline, disciplined capital allocation, strong operational execution.
EPS
Actual | -0.13 | -0.13 | -0.13 | -0.15 | -0.19 | -0.2 | -0.17 | -0.16 | -0.21 | -0.23 | -0.21 | -0.26 | -0.25 | -0.19 | -0.23 | -0.25 | -0.26 | -0.2 | -0.22 | -0.32 | -0.41 | -0.58 | -0.81 | -1.38 | |||||||||||
Forecast | -0.1218 | -0.1433 | -0.152 | -0.1524 | -0.1736 | -0.1962 | -0.21 | -0.187 | -0.192 | -0.212 | -0.233 | -0.2323 | -0.2402 | -0.1927 | -0.219 | -0.254 | -0.2767 | -0.2626 | -0.2429 | -0.2759 | -0.328 | -0.4465 | -0.7096 | -0.8972 | |||||||||||
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -6.73% | +9.28% | +14.47% | +1.57% | -9.45% | -1.94% | +19.05% | +14.44% | -9.38% | -8.49% | +9.87% | -11.92% | -4.08% | +1.40% | -5.02% | +1.57% | +6.04% | +23.84% | +9.43% | -15.98% | -25.00% | -29.90% | -14.15% | -53.81% |
Revenue
Actual | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Forecast | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Earnings Call
You can ask Aime
What does Viking Therapeutics do and what are its main business segments?What were the key takeaways from Viking Therapeutics's earnings call?What is the market's earnings forecast for Viking Therapeutics next quarter?Did Viking Therapeutics beat or miss consensus estimates last quarter?What guidance did Viking Therapeutics's management provide for the next earnings period?What were the key takeaways from Viking Therapeutics’s earnings call?What factors drove the changes in Viking Therapeutics's revenue and profit?What is the revenue and EPS growth rate for Viking Therapeutics year over year?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
